THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.
Identifying clonality and determining the frequency of immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements is crucial in understanding lymphoproliferative diseases.1 These gene rearrangements serve as markers for clonal lymphocyte populations, aiding in the detection of blood cancers.2,3 The introduction of next-generation sequencing (NGS) has enhanced sensitivity and specificity in clonality assessment, allowing a more comprehensive analysis of Ig and TCR gene rearrangements, facilitating the detection of clonal populations even in samples with low tumour cell content. Recent improvements in NGS clonality assays include providing molecular evidence of clonality in malignant or suspect lymphoproliferative disorders and facilitating measurable residual disease (MRD) assessment.1,4
The LymphoTrack® Flex Assays for haemato-oncology research represent highly sensitive, NGS reagents that accurately identify gene rearrangement diversity and clonality. Designed to be used with the Illumina® NextSeq™1000 System to provide flexibility, scalability and workflow efficiencies for high-throughput laboratories as well as additional applications (such as MRD with DNA input volume flexibility).
LymphoTrack Flex Assay kits can process a total of 96 samples and controls. The supplementary Linux-based LymphoTrack Enterprise Software analysis generates output files that can be easily transferred into a LIMS for automated reporting.
LymphoTrack Flex Assays are for Research Use Only (RUO). Not intended for diagnostic or therapeutic use.
Reference
1. Groenen, PTJA et al. Fron. Oncol. 2023 Feb 07;13:2234-2243.
2. Fan, H, Robetorye, RS. Methods in Molecular Biology: 2013;999:151-67.
3. Teramo A, et al. Nat Commun. 2022 Jun 8;13(1):3298.
4. Faham M, et al. Blood. 2012 Dec 20;120(26):5173-80.
